Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin

Anetta Undas; Ewa Placzkiewicz-Jankowska; Lukasz Zieliński; Wieslawa Tracz

doi:10.1160/TH07-01-0047

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 97(06): 1056-1058
DOI: 10.1160/TH07-01-0047

Letters to the Editor

Schattauer GmbH

Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin

Anetta Undas

¹Institute of Cardiology

,

Ewa Placzkiewicz-Jankowska

²Department of Endocrinology, Jagiellonian University School of Medicine, Krakow, Poland

,

Lukasz Zieliński

³John Paul II Hospital, Krakow, Poland

,

Wieslawa Tracz

¹Institute of Cardiology

› Author Affiliations

Abstract

Full Text

References

References
1 Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007; 109: 285-22.
2 Kyrle PA, Westwick J, Scully MF. et al Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation ex vivo in man: effect of low-dose aspirin. Thromb Haemost 1987; 57: 62-69.
3 Undas A, Brummel K, Musial J. et al Blood coagulation at the site of microvascular injury: effects of lowdose aspirin. Blood 2001; 98: 2423-2431.
4 Szczeklik A, Musial J, Undas A. et al Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33: 1286-1293.
5 Musial J, Undas A, Undas R. et al Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. Thromb Haemost 2001; 85: 221-225.
6 Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-617.
7 McKee SA, Sane Dc, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88: 711-715.
8 Tantry US, Blinden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705-1709.
9 Undas A, Brummel KE, Musial J. et al Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-2253.
10 Undas A, Undas R, Musial J. et al A low dose of aspirin (75 mg/day) lowers thrombin generation to a similar similar extent as a high dose of aspirin (300 mg/day). Blood Coagul Fibrinolysis 2000; 11: 231-234.
11 Szczeklik A, Musial J, Undas A. et al Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16: 948-954.
12 Friend M, Vucenik I, Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. Br Med J 2003; 326: 82-83.
13 Williams PC, Coffey MJ, Coles B. et al In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets. Blood 2005; 106: 2737-2743.
14 Undas A, Celinska-Lowenhoff M, Kaczor M. et al New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 2004; 91: 1065-1077.
15 Patrono C, Rocca B. Drug insight: aspirin resistance – fact or fashion?. Nat Clin Pract Cardiovasc Med 2007; 4: 42-70.